Cargando…

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database

PURPOSE: Elagolix is an oral gonadotropin-releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real-world evaluation of the demographic and clinical characteristics of women diagnosed with endometriosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Surrey, Eric S, Soliman, Ahmed M, Johns, Beverly, Vora, Jamie B, Taylor, Hugh S, Agarwal, Sanjay K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456657/ https://www.ncbi.nlm.nih.gov/pubmed/32922052 http://dx.doi.org/10.2147/CEOR.S264905

Ejemplares similares

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
por: Archer, David F., et al.
Publicado: (2020)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials
por: Surrey, Eric S., et al.
Publicado: (2019)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
por: Abrao, Mauricio S., et al.
Publicado: (2021)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
por: Kilpatrick, Ryan D, et al.
Publicado: (2020)

Levothyroxine Treatment of Pregnant Women with Hypothyroidism: Retrospective Analysis of a US Claims Database
por: Lage, Maureen J., et al.
Publicado: (2020)

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis
por: Surrey, Eric S., et al.
Publicado: (2017)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
por: Abbas Suleiman, Ahmed, et al.
Publicado: (2020)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Real-world characteristics of women with endometriosis-related pain entering a multidisciplinary endometriosis program
por: Agarwal, Sanjay K., et al.
Publicado: (2021)

Hypothyroidism Treatment Among Older Adults: Evidence from a Claims Database
por: Lage, Maureen J., et al.
Publicado: (2020)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
por: Imel, E.A., et al.
Publicado: (2020)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Patients’ perspectives of endometriosis-related fatigue: qualitative interviews
por: DiBenedetti, Dana, et al.
Publicado: (2020)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims Database
por: Brailean, Anamaria, et al.
Publicado: (2023)

Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs
por: Surrey, Eric, et al.
Publicado: (2020)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

Real-World Cataract Surgery Complications and Secondary Interventions Incidence Rates: An Analysis of US Medicare Claims Database
por: Terveen, Daniel, et al.
Publicado: (2022)

Health claims databases used for kidney research around the world
por: van Oosten, Manon J M, et al.
Publicado: (2020)

Endometriosis-Related Infertility: The Role of the Assisted Reproductive Technologies
por: Surrey, Eric S.
Publicado: (2015)

O8.5. SCHIZOPHRENIA AND BIPOLAR DISORDER DIAGNOSIS PATTERNS: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

GnRH agonists in the treatment of symptomatic endometriosis: a review
por: Surrey, Eric S.
Publicado: (2022)

Chronic opioid use and complication risks in women with endometriosis: A cohort study in US administrative claims
por: Chiuve, Stephanie E., et al.
Publicado: (2021)

Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
por: Wu, Jashin J., et al.
Publicado: (2022)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oaes2hg5ih8sa98ffpeteh66a1